| 14.07 0.92 (7%) | 04-01 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 16.9 | 1-year : | 18.34 |
| Resists | First : | 14.47 | Second : | 15.71 |
| Pivot price | 13.54  |
|||
| Supports | First : | 12.47 | Second : | 10.37 |
| MAs | MA(5) : | 13.4 |
MA(20) : | 13.68 |
| MA(100) : | 15.1 |
MA(250) : | 12.54 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 36.3 |
D(3) : | 29.6 |
| RSI | RSI(14): 52.1 |
|||
| 52-week | High : | 18.97 | Low : | 7.56 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NPCE ] has closed below upper band by 18.8%. Bollinger Bands are 40.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 14.14 - 14.2 | 14.2 - 14.26 |
| Low: | 13.13 - 13.18 | 13.18 - 13.25 |
| Close: | 13.96 - 14.05 | 14.05 - 14.16 |
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
Wed, 01 Apr 2026
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Wed, 25 Mar 2026
NeuroPace (NPCE) CMO has 1,341 shares withheld for RSU tax - Stock Titan
Mon, 23 Mar 2026
NeuroPace (NPCE) director gets 1,153-share stock grant as board fees - Stock Titan
Mon, 23 Mar 2026
NeuroPace (NPCE) director receives 1,826-share equity grant in lieu of cash fees - Stock Titan
Thu, 19 Mar 2026
NeuroPace (NASDAQ:NPCE) Upgraded at Wells Fargo & Company - MarketBeat
Wed, 18 Mar 2026
How The NeuroPace (NPCE) Story Is Shifting As Analysts Refresh Valuation Assumptions - finance.yahoo.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 34 (M) |
| Shares Float | 23 (M) |
| Held by Insiders | 2.6 (%) |
| Held by Institutions | 95 (%) |
| Shares Short | 939 (K) |
| Shares Short P.Month | 869 (K) |
| EPS | -0.67 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.56 |
| Profit Margin | -21.5 % |
| Operating Margin | -6.7 % |
| Return on Assets (ttm) | -10.2 % |
| Return on Equity (ttm) | -158.8 % |
| Qtrly Rev. Growth | 23.8 % |
| Gross Profit (p.s.) | 2.29 |
| Sales Per Share | 2.96 |
| EBITDA (p.s.) | -0.48 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -21.32 |
| PEG Ratio | 0 |
| Price to Book value | 24.68 |
| Price to Sales | 4.73 |
| Price to Cash Flow | -43.03 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|